Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer

Tumor Biology

Volumn 37, Issue 9, 2016, Pages 12203-12211

  Ke, Jieqi ^a   Yang, Yixia ^a   Che, Qi ^a   Jiang, Feizhou ^a   Wang, Huihui ^a   Chen, Zheng ^a   Zhu, Minjiao ^a   Tong, Huan ^a   Zhang, Huilin ^a   Yan, Xiaofang ^a   Wang, Xiaojun ^a   Wang, Fangyuan ^a   Liu, Yuan ^a   Dai, Chenyun ^a   Wan, Xiaoping ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai First Maternity and Infant Health Hospital   (China)

Author keywords

Endometrial cancer; EP4; Prostaglandin E2; SUMO 1; catenin

Indexed keywords

BETA CATENIN; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E SYNTHASE 2; PROSTAGLANDIN E2; SHORT HAIRPIN RNA; SUMO 1 PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER TISSUE; CELL COUNTING; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUMOYLATION; UTERUS SURGERY; WESTERN BLOTTING; WNT SIGNALING PATHWAY; DRUG EFFECTS; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DINOPROSTONE; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PROSTAGLANDIN-E SYNTHASES; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SUMO-1 PROTEIN;

EID: 84969988399     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5087-x     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
3. Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in china, 2011. Chinese journal of cancer research. Chung-kuo yen cheng yen chiu. 2015;27:2–12.
4. Legler DF, Bruckner M, Uetz-von Allmen E, Krause P. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol. 2010;42:198–201.
5. Doherty GA, Byrne SM, Molloy ES, Malhotra V, Austin SC, Kay EW, et al. Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. BMC Cancer. 2009;9:207.
6. Frasor J, Weaver AE, Pradhan M, Mehta K. Synergistic up-regulation of prostaglandin e synthase expression in breast cancer cells by 17β-estradiol and proinflammatory cytokines. Endocrinology. 2008;149:6272–9.
7. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K. Ovarian epithelial cancer: a role for pge2-synthesis and signalling in malignant transformation and progression. Mol Cancer. 2006;5:62.
8. Che Q, Liu BY, Liao Y, Zhang HJ, Yang TT, He YY, et al. Activation of a positive feedback loop involving il-6 and aromatase promotes intratumoral 17β-estradiol biosynthesis in endometrial carcinoma microenvironment. Int J Cancer. 2014;135:282–94.
9. Zhu M, Che Q, Liao Y, Wang H, Wang J, Chen Z, et al. Oncostatin M activates STAT3 to promote endometrial cancer invasion and angiogenesis. Oncol Rep. 2015;34:129–38.
10. Takahashi T, Ogawa H, Izumi K, Uehara H. The soluble EP2 receptor FuEP2/Ex2 suppresses endometrial cancer cell growth in an orthotopic xenograft model in nude mice. Cancer Lett. 2011;306:67–75.
11. Sales KJ, Battersby S, Williams AR, Anderson RA, Jabbour HN. Prostaglandin E2 mediates phosphorylation and down-regulation of the tuberous sclerosis-2 tumor suppressor (tuberin) in human endometrial adenocarcinoma cells via the Akt signaling pathway. J Clin Endocrinol Metab. 2004;89:6112–8.
12. Yang WS, Hsu HW, Campbell M, Cheng CY, Chang PC. K-bZIP mediated sumo-2/3 specific modification on the KSHV genome negatively regulates lytic gene expression and viral reactivation. PLoS Pathog. 2015;11:e1005051.
13. Georges A, Benayoun BA, Marongiu M, Dipietromaria A, L’Hote D, Todeschini AL, et al. SUMOylation of the Forkhead transcription factor FOXl2 promotes its stabilization/activation through transient recruitment to PML bodies. PLoS One. 2011;6:e25463.
14. Gill G. Sumo weighs in on polycomb-dependent gene repression. Mol Cell. 2010;38:157–9.
15. Hay RT. Sumo: a history of modification. Mol Cell. 2005;18:1–12.
16. Matunis MJ, Coutavas E, Blobel G. A novel ubiquitin-like modification modulates the partitioning of the ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol. 1996;135:1457–70.
17. Johnson ES, Schwienhorst I, Dohmen RJ, Blobel G. The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J. 1997;16:5509–19.
18. Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. A small ubiquitin-related polypeptide involved in targeting RsanGAP1 to nuclear pore complex protein RanBP2. Cell. 1997;88:97–107.
19. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 1999;18:6455–61.
20. Miao L, Shi J, Wang CY, Zhu Y, Du X, Jiao H, et al. Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells. Mol Endocrinol. 2010;24:1175–86.
21. Shi Q, Yin Z, Zhao B, Sun F, Yu H, Yin X, et al. PGE2 elevates IL-23 production in human dendritic cells via a camp dependent pathway. Mediat Inflamm. 2015;2015:984690.
22. Fujino H, Seira N, Kurata N, Araki Y, Nakamura H, Regan JW, et al. Prostaglandin E2-stimulated prostanoid EP4 receptors induce prolonged de novo prostaglandin E2 synthesis through biphasic phosphorylation of extracellular signal-regulated kinases mediated by activation of protein kinase a in HCA-7 human colon cancer cells. Eur J Pharmacol. 2015;768:149–59.
23. Leitao B, Jones MC, Fusi L, Higham J, Lee Y, Takano M, et al. Silencing of the JNK pathway maintains progesterone receptor activity in decidualizing human endometrial stromal cells exposed to oxidative stress signals. FASEB J. 2010;24:1541–51.
24. Jones MC, Fusi L, Higham JH, Abdel-Hafiz H, Horwitz KB, Lam EW, et al. Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. Proc Natl Acad Sci U S A. 2006;103:16272–7.
25. Zhan Y, Liu Y, Wang C, Lin J, Chen M, Chen X, Zhuang C, Liu L, Xu W, Zhou Q, Sun X, Zhang Q, Zhao G, Huang W: Increased expression of sumo1p3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. Oncotarget 2016. doi:10.18632/oncotarget.6946
26. Lin C, Crawford DR, Lin S, Hwang J, Sebuyira A, Meng R, et al. Inducible COX-2-dependent apoptosis in human ovarian cancer cells. Carcinogenesis. 2011;32:19–26.
27. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
29. Yang C, He L, He P, Liu Y, Wang W, He Y, et al. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/BCL-2 signaling pathway. Med Oncol. 2015;32:352.
30. von Euler US. On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J Physiol. 1936;88:213–34.
31. Kim JI, Lakshmikanthan V, Frilot N, Daaka Y. Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Mol Cancer Res. 2010;8:569–77.
32. Li S, Xu X, Jiang M, Bi Y, Xu J, Han M. Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2–Ep2 pathway. Mol Med Rep. 2015;11:4454–62.
33. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, et al. Cyclooxygenase-2 expression and prostaglandin e(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab. 2001;86:2243–9.
34. Trabanelli S, Lecciso M, Salvestrini V, Cavo M, Ocadlikova D, Lemoli RM, et al. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. Int J Immunol Res. 2015;2015:253191.
35. Modugno F, Ness RB, Chen C, Weiss NS. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2005;14:2840–7.
36. Brasky TM, Moysich KB, Cohn DE, White E. Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the vitamins and lifestyle (vital) cohort. Gynecol Oncol. 2013;128:113–9.
37. Johnson ES. Protein modification by SUMO. Annu Rev Biochem. 2004;73:355–82.
38. Zheng J, Liu L, Wang S, Huang X. SUMO-1 promotes Ishikawa cell proliferation and apoptosis in endometrial cancer by increasing SUMOylation of histone H4. Int J Gynecol Cancer. 2015;25:1364–8.
39. Picard N, Caron V, Bilodeau S, Sanchez M, Mascle X, Aubry M, et al. Identification of estrogen receptor beta as a SUMO-1 target reveals a novel phosphorylated SUMOylation motif and regulation by glycogen synthase kinase 3β. Mol Cell Biol. 2012;32:2709–21.
40. Liu HW, Zhang J, Heine GF, Arora M, Gulcin Ozer H, Onti-Srinivasan R, et al. Chromatin modification by SUMO-1 stimulates the promoters of translation machinery genes. Nucleic Acids Res. 2012;40:10172–86.
41. Agbor TA, Cheong A, Comerford KM, Scholz CC, Bruning U, Clarke A, et al. Small ubiquitin-related modifier (SUMO)-1 promotes glycolysis in hypoxia. J Biol Chem. 2011;286:4718–26.
42. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.
43. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol. 2011;38:243–53.
44. Eskander RN, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, et al. Expression patterns of the wnt pathway inhibitors Dickkopf3 and secreted frizzled-related proteins 1 and 4 in endometrial endometrioid adenocarcinoma: an NRG oncology/gynecologic oncology group study. Int J Gynecol Cancer. 2016;26:125–32.